Statement: the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 13/74 (17.57%)   neutropenia 1/74 (1.35%)   left ventricular dysfunction 1/74 (1.35%)   fistula enterovesical 1/74 (1.35%)   constipation and hypokalemia 1/74 (1.35%)   nausea, vomiting and burning abdominal pain 2/74 (2.70%)   Infection 1/74 (1.35%)   febrile neutropenia 3/74 (4.05%)   speech impairment 1/74 (1.35%)   dyspnea, pain 1/74 (1.35%)   hemorrhage/bleeding 2/74 (2.70%)
Secondary_evidence: Adverse Events 1:   Total: 11/50 (22.00%)   Anemia 3/50 (6.00%)   Febrile neutropenia 1/50 (2.00%)   Arrythmia 1/50 (2.00%)   Ileus 1/50 (2.00%)   Nausea 1/50 (2.00%)   Pain-Abdominal 1/50 (2.00%)   Vomiting 1/50 (2.00%)   Bronchial infection 1/50 (2.00%)   Sepsis 1/50 (2.00%)   Neutropenia 2/50 (4.00%)   Platelet count decreased 1/50 (2.00%)   Dehydration 1/50 (2.00%)   Arthralgia 1/50 (2.00%)